TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04315961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded drug dose conditions
Description: Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Blinded drug dose conditions
Description: Capsules will contain commonly prescribed or over-the-counter drugs or placebo. Capsules in this study may contain sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, or antihistamines which must remain blinded for the purposes of this study.
Study: NCT01950598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Boston KPro type I - fresh graft
Description: Boston KPro mounted on fresh corneal carrier graft for implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Boston KPro type I surgery - frozen graft
Description: Boston KPro mounted on frozen corneal carrier graft for implantation
Study: NCT02799979

Intervention type: DEVICE
Intervention: 3D right ventricular imaging echocardiographic
Description: Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
Study: NCT04098913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced screen-based media use
Description: Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
Study: NCT03992482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immune Globulin (IVIG)
Description: Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
Study: NCT04456010

Intervention type: OTHER
Intervention: Questionnaire
Description: Eligible patients will be selected from our electronical database and invited via email to participate.
Study: NCT00657254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
Study: NCT03809923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Patients received IV bolus infusion of dexmedetomidine 0.5 μg/kg made to 20ml with normal saline and 20ml normal saline respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4μg/kg made up to 20ml and 20ml normal saline every houruntil 30 min before the end of operation, respectively.
Study: NCT01177332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 2 hours cycling exercise at 50 % of maximal power output

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: 2 hours cycling exercise at 50 % of maximal power output
Study: NCT02401139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02909179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mCARE-II
Description: mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
Study: NCT00704808

Intervention type: PROCEDURE
Intervention: Primary surgical treatment
Description: Primary surgery for tumor resection.

Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.

Intervention type: DRUG
Intervention: Temozolomide
Description: Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
Study: NCT02653378

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIET
Description: 25% Energy Depletion by Diet only for 3 Days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EX
Description: 25% Energy Depletion by Exercise only for 3 Days
Study: NCT01242020

Intervention type: DRUG
Group type: OTHER
Intervention: Perflutren Lipid Microsphere Injectable Suspension
Description: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used

Intervention type: DRUG
Group type: OTHER
Intervention: Perflutren Lipid Microsphere Injectable Suspension
Description: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
Study: NCT03777579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001，an engineered anti-PD-1 antibody
Description: JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Study: NCT03201627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
Study: NCT04466228

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non-invasive transcranial electrical stimulation
Description: Non-invasive transcranial electrical stimulation across the prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial electrical stimulation
Description: Non-invasive transcranial electrical stimulation across the prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial electrical stimulation
Description: Non-invasive transcranial electrical stimulation across the prefrontal cortex.
Study: NCT03777579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Study: NCT04454996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tong-jiang granules
Description: This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chang 'an II Recipe
Description: This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo of tong-jiang granules
Description: This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
Study: NCT01119625

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, one dose
Study: NCT04021407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA group
Description: patients were ventilated with LMA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirQ group
Description: patients were ventilated with AirQ airway
Study: NCT02629640

Intervention type: OTHER
Intervention: Medical history questionnaire
Description: Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.

Intervention type: OTHER
Intervention: Clinical assessment and review
Description: History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.

Intervention type: OTHER
Intervention: Participant follow-up
Description: Hospital patient management system; regular telephone contact with patient/representative.

Intervention type: OTHER
Intervention: Blood or buccal sample
Description: Codon-129 genotyping; storage for future research.

Intervention type: OTHER
Intervention: Post mortem examination
Description: Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
Study: NCT01721772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558 (Nivolumab)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching BMS-936558 (Nivolumab)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Dacarbazine
Study: NCT04485819

Intervention type: OTHER
Intervention: Cleavage stage transfer
Description: transferring embryos through ICSI procedures for poor responders on cleavage stage of embryonic development.

Intervention type: OTHER
Intervention: Blast stage transfer
Description: transferring embryos through ICSI procedures for poor responders on blast stage of embryonic development.
Study: NCT04547036

Intervention type: DEVICE
Intervention: XEN45
Description: Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
Study: NCT04280224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)
Study: NCT02713139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole + Metronidazole
Description: Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
Study: NCT03349632

Intervention type: DEVICE
Group type: OTHER
Intervention: verofilcon A contact lenses
Description: Investigational spherical silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: verofilcon A contact lenses
Description: Investigational spherical silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: verofilcon A contact lenses
Description: Investigational spherical silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: senofilcon A contact lenses
Description: Commercially available spherical silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: stenfilcon A contact lenses
Description: Commercially available spherical silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A contact lenses
Description: Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
Study: NCT03369132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiflash
Description: throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
Study: NCT04104360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides
Description: During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
Study: NCT03326167

Intervention type: OTHER
Intervention: Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)
Description: Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
Study: NCT00697619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa (zoledronic acid)
Description: Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
Study: NCT03324815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Pain Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Pain Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Pain Treatment
Study: NCT01940445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 ResurFX
Description: Fractional NA treatment (ResurFX) on one side of the face

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22 ResurFX and QS
Description: Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
Study: NCT03224624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-management protocol for hypertension care
Description: participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
Study: NCT02375945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New non-elastic compression kit
Description: Comparison of new non-elastic bandage kit with the currently accepted method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New non-elastic compression kit
Description: Comparison of new non-elastic bandage kit with the currently accepted method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: current compression stocking Comprinet®
Description: Comparison of new non-elastic bandage kit with the currently accepted method

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: current compression stocking Comprinet®
Description: Comparison of new non-elastic bandage kit with the currently accepted method
Study: NCT02248012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus , temozolomide
Study: NCT04232540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedViewer report
Description: Results from the analysis of hair samples performed using the MedViewer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedViewer report
Description: Results from the analysis of hair samples performed using the MedViewer
Study: NCT02378909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation device.
Description: In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation device.
Description: In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
Study: NCT01285076

Intervention type: OTHER
Intervention: Other: Retrospective chart review; one participant encounter visit.
Description: Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
Study: NCT02926755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Angiography
Description: Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
Study: NCT01611896

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
Study: NCT04045015

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liqourice
Description: Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liqourice
Description: Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
Study: NCT02877537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
Study: NCT04045015

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liqourice
Description: Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
Study: NCT01394133

Intervention type: DRUG
Intervention: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Description: Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
Study: NCT03867773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
Study: NCT01992094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIVc
Description: Novartis Investigational Quadrivalent Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV1c
Description: Licensed Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV2c
Description: Novartis Investigational Vaccine